News Release

Speed, evidence, safety characteristics of vaccine approvals by FDA

Peer-Reviewed Publication

JAMA Network

What The Study Did: Amid an urgent need to develop a safe and effective vaccine to prevent COVID-19, researchers evaluated all new vaccines approved by the U.S. Food and Drug Administration over the last decade, characterizing premarket development and regulatory review times, the clinical evidence on which approval was based, and the size and follow-up duration of the prelicensure safety database.

Authors: Joseph S. Ross, M.D., M.H.S., of the Yale University School of Medicine in New Haven, Connecticut, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link


Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.


Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.